Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
Alterity Therapeutics Granted New US Patent for Compounds for Neurodegenerative Diseases Including Parkinson's and Alzheimer's 2022-01-06 20:30
Alterity Therapeutics to Present at the H.C. Wainwright BIOCONNECT Virtual Conference 2022-01-05 20:45
Alterity Therapeutics Announces First Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial 2021-12-14 20:25
Alterity Therapeutics to Participate in Two Upcoming Investor Conferences 2021-11-22 20:50
Alterity Therapeutics Announces Presentation of ATH434 at the American Autonomic Society Virtual Meeting 2021 2021-11-09 20:30
Alterity Therapeutics Announces New Publications Providing Further Evidence of the Potential of ATH434 to Treat Neurodegenerative Diseases 2021-11-05 14:57
Alterity Therapeutics Announces New Publications Providing Further Evidence of the Potential of ATH434 to Treat Neurodegenerative Diseases 2021-11-04 19:30
Appendix 4C - Q1 FY22 Quarterly Cash Flow Report 2021-10-29 14:50
Alterity Therapeutics Announces Expanded ATH434 Phase 2 Clinical Development Program 2021-10-20 05:08
Alterity Announces Presentation of Biomarker Data at the International Parkinson and Movement Disorder Society Congress 2021 2021-09-20 22:51
Alterity Therapeutics Announces New US Patent to Expand its Portfolio of Compounds for Neurodegenerative Diseases including Alzheimer's and Parkinson's 2021-08-04 20:39
Appendix 4C - Q4 FY21 Quarterly Cash Flow Report 2021-07-30 21:05
Alterity Therapeutics Announces Publication of Data Demonstrating ATH434 is Neuroprotective and Improves Motor Function 2021-07-15 21:52
Alterity Therapeutics granted a new US patent targeting major neurodegenerative diseases including Alzheimer's and Parkinson's 2021-07-01 19:50
Alterity Therapeutics Limited Received European Union Regulatory Guidance for ATH434 Phase 2 Clinical Trial 2021-06-23 21:21
Alterity Therapeutics Limited Appendix 4C - Q3 FY21 Quarterly Cash Flow Report 2021-04-29 20:30
ATH434 protects brain cells and improves motor function in Parkinsonian disorder 2021-04-21 20:11
Alterity to present at the 7th International Congress of Multiple System Atrophy 2021-02-26 20:45
Alterity Therapeutics announces funding from Michael J. Fox Foundation for ATH434 dose optimization for Parkinson's disease clinical trials 2021-02-09 21:53
Dr David Stamler Appointed CEO 2021-01-07 21:00
1 2 3